JAK2 and systemic lupus erythematosus: Moreover, inhibitors of JAK2, which is a kinase upstream of STAT3, are currently in clinical trials to treat SLE [53], as well as open clinical trials (NCT03616912 [Last Update 20/01/2021], NCT03616964 [Last Update 19/10/2020]).